Company Profile

Member Since

  • 2018

Company Affiliation

  • Parent

Membership Category

  • Pharmaceutical Sales and Mfg

Contact Information

New York, NY 10018


  • Enzyvant Sciences Ltd is a biopharmaceutical company focused on the treatment of patients with Farber disease. The company's mission is to develop transformative therapies for rare diseases with high unmet needs. It was formed on July 12, 2016 by Roivant Sciences and Plexcera Therapeutics. The company is a trading name of Roivant Ultra Orphan Ltd. Enzyvant is developing recombinant human acid ceramidase (rhAC), an enzyme replacement therapy for Farber disease. Its pipeline products include: RVT-802, is a biologic therapy and RVT-801, is a recombinant form of human acid ceramidase (rhAC) for use as an enzyme replacement therapy in acid ceramidase deficiency (ACD), which manifests as Farber disease.

Number of Employees

  • 50 - 499